Clinical trials: COVID-19, SARS-CoV-2
Virus Diseases
Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)
Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of modulating the immune system, exerting an anti-inflammatory effect in different diseases.
- Trial name
- COVIMAR (NCT04710199)
- Testing
- Maraviroc experimental group, Standard treatment
- Where
- 2 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
COVID19, Diabetes Mellitus
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
The disease caused by SARS-CoV-2, has derived a pandemic in which its evolution and complications depend on the immune capacity of the host.
- Conditions
- COVID19, Diabetes Mellitus, Hypertension, Obesity
- Trial name
- NCT04507867
- Testing
- Nutritional support system (NSS), Conventional nutritional support designed by hospital nutritionists
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- Anahuac University
COVID 19
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)
- Trial name
- NCT04343092
- Testing
- Ivermectin (IVM)
- Where
- Iraq
- Volunteers
- 16 people
- Sponsor
- University of Baghdad
COVID-19, Severe Acute Respiratory Syndrome (SARS)
ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS)
The goal of this study is to evaluate the safety and effectiveness of Coronavirus-90 (COVID-19) convalescent plasma for the treatment of COVID-19.
- Conditions
- COVID-19, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
- Trial name
- ABACCuS (NCT04432272)
- Testing
- COVID-19 convalescent plasma
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Corewell Health East
SARS-CoV-2 Infection
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
The mortality rate of the disease caused by the corona virus induced disease (COVID-19) has been estimated to be 3.7% (WHO), which is more than 10-fold higher than the mortality of influenza.
- Trial name
- CORON-ACT (NCT04335071)
- Testing
- Tocilizumab (TCZ)
- Where
- 4 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
COVID-19, COVID-19 Pandemic
Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2
The purpose of the study is to conduct a prospective evaluation of the diagnostic performance of the IVD CAPSULE COVID-19-NP test for antigenic determination of SARS-CoV-2 virus on the abioSCOPE® instrument.
- Trial name
- NCT05596032
- Where
- Italy
- Volunteers
- 440 people
- Sponsor
- Abionic SA
Long COVID, Post-COVID Conditions
Transcranial Direct Current Stimulation for Long COVID Brain Fog and Fatigue
Long COVID can cause persistent symptoms such as fatigue, cognitive difficulties commonly described as brain fog, reduced exercise tolerance, and impaired quality of life.
- Conditions
- Long COVID, Post-COVID Conditions, Fatigue, Cognitive Dysfunction
- Trial name
- NEUROSTIM-LC (NCT07709234)
- Testing
- Transcranial Direct Current Stimulation
- Volunteers
- 20 people
- Sponsor
- University of Las Palmas de Gran Canaria
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04312009
- Testing
- Losartan
- Where
- 13 sites in United States
- Volunteers
- 205 people
- Sponsor
- University of Minnesota
Viral Disease
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
- Trial name
- NCT04535167
- Testing
- PF-07304814
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 26 people
- Sponsor
- Pfizer
Covid19, SARS CoV 2 Infection
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
This is a first-in-human, phase I/IIa, randomized, controlled, observer-blinded, dose-escalation, multicentre clinical trial to evaluate safety and immunogenicity of COVID-19 HIPRA vaccine in adult healthy volunteers.
- Trial name
- NCT05007509
- Testing
- COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40
- Where
- 2 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Hipra, S.A.
COVID-19, SARS-CoV-2 Infection
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Solid Organ Transplant, Vaccine Response Impaired
- Trial name
- NCT05124509
- Testing
- Three doses of SARS-CoV-2 BNT162b2 vaccine (observational), Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)
- Where
- Chile
- Volunteers
- 147 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198063
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Pregnancy Complications, Covid19
Vitamin D Supplementarion in Pregnant Women at Risk and COVID-19
Vitamin D defiency during pregnancy is a major public health problem worldwide; In Spain, the average intake of vitamin D is lower than recommendations in an elevated percentage of the population, ranging from 50 to 95%…
- Trial name
- D-WOMAN (NCT04825093)
- Testing
- Vitamin D supplementation in pregnant women
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
COVID, Pneumonia
SEVERITY SCORE FOR COVID-19 PNEUMONIA
The outbreak of the coronavirus disease 2019 (COVID-19), first merged in China in December 2019, is now becoming a Public Health Emergency, recently confirmed as a pandemic disease by the World Health Organization.
- Trial name
- NCT04372199
- Where
- Italy
- Volunteers
- 248 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
SARS-COV-2 Infections, COVID-19
Fight COVID-19 Trial
A 6-Week Prospective, Open label, Randomized, in Multicenter Study of, Oseltamivir 300mg per day plus Hydroxychloroquine 800 mg per day versus Combination of Lopipinavir 800mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5…
- Trial name
- FIGHT-COVID-19 (NCT04303299)
- Testing
- Oral
- Where
- Thailand
- Volunteers
- 320 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
SARS-CoV2 Infection, COVID-19, Gut Microbiota, Mucosal Response, Children
COVID-19 and Intestinal Microbiota in Children
SARS-CoV-2 is the causative agent of the COVID-19 pandemic. It appears to cause only mild to moderate upper respiratory symptoms in children, in addition to gastrointestinal symptoms resulting from its penetration into intestinal…
- Trial name
- NCT06503887
- Testing
- Stool sample collection
- Where
- Lebanon
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Saint-Joseph University
Acute Respiratory Distress Syndrome
Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU
Renal damage in patients hospitalized for ARDS in the ICU can also be related to multiple causes including, but not limited to, the consequences of hemodynamic fluctuations in these patients or the use of nephrotoxic drugs…
- Trial name
- PR-Covid-19 (NCT04385004)
- Where
- France
- Volunteers
- 320 people
- Sponsor
- University Hospital, Strasbourg, France
Adult Patients With Lesions on Fingers or Toes
Clinical and Mechanistic Study of Patients (With COVID-19 or Not) With a Recent Acrosyndrome
The recent and unexpected occurrence of patients with the development of skin lesions on the hands and/ or feet has been described recently.
- Trial name
- ACROCOVID (NCT04590209)
- Testing
- Blood sampling, Skin biopsy
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy Volunteers
Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)
A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
- Trial name
- NCT04679909
- Testing
- AdCOVID
- Where
- 6 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
COVID-19 Vaccines
Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes
To determine whether a heterologous vaccination regimen in individuals with no known previous history of COVID-19 is non-inferior to that observed with counterpart regimens currently in use in Argentina.
- Trial name
- NCT04962906
- Testing
- Gam-COVID-Vac / Gam-COVID-Vac
- Where
- Argentina
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Ministerio de Salud de Ciudad Autónoma de Buenos Aires
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.